Puma BiotechnologyCOVID-19 UPDATE

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to

Home About Us Pipeline News Investors Contacts Careers

NOW APPROVED FOR PATIENTS IN THE UNITED STATES WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER
Approved for Commerical Sale in the European UnionFor more information on NERNLYNX
Corporate Fact Sheet

RECENT NEWSEVENTSCLINICAL TRIALS


May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results
Read

May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Read

May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020
Read

April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Read

April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read

February 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read

February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Read

February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results
Read

Upcoming Events

May 7, 2020 - Puma Biotechnology 1Q-2020 Financial Results Conference Call
More

May 13, 2020 - BofA Securities Health Care Conference 2020
More


Past Events

March 4, 2020 - Cowen and Company 40th Annual Health Care Conference
More

Feb. 20, 2020 - Puma Biotechnology 4Q-2019 Financial Results Conference Call
More

Jan. 15, 2020 - 38th Annual J.P. Morgan Healthcare Conference
More

Dec. 10, 2019 - San Antonio Breast Cancer Symposium
More

Nov. 12, 2019 - Credit Suisse 28th Annual Healthcare Conference
More

Nov. 6, 2019 - Puma Biotechnology 3Q-2019 Financial Results Conference Call
More

October 3, 2019 - Cantor Global Healthcare Conference
More

 Puma-Sponsored Trials
Investigator-Sponsored Trials



Annual Report

2019 Annual Report

 Annual Report Archives

Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com

Business Development:
info@pumabiotechnology.com

Investor Relations:
ir@pumabiotechnology.com




© 2020 Puma Biotechnology, Inc. | Privacy Policy | Legal Notice | Site Map